Biopharmaceutical and Biomedicine Market Insights, and Forecast to 2025

Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment and rise in per capita healthcare expenditure has led to double digit revenue growth for industry players in the recent past. The industry offers lucrative growth opportunities, since most of these products still have low penetration rate. The market is expected to gain further traction, with evolving treatment archetypes and rapid technological innovation such as cell therapy and regenerative medicines.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/18

Launches and approvals of novel biopharmaceutical and biomedicine products is expected to drastically drive growth of global biopharmaceutical and biomedicine market in the near future. For instance, in 2016, Sanofi S.A. received U.S. FDA approval for its Adlyxin ((lixisenatide) injection. Adlyxin is indicated to improve blood sugar levels among adults suffering from type 2 diabetes. In 2016, Johnson & Johnson received U.S. FDA approval for its Stelara (Ustekinumab), indicated for the treatment of adults suffering from moderately to severely active crohn’s disease. In 2016, CSL Behring received U.S. FDA approval for its IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein. IDELVION is indicated for the treatment of Hemophilia B among children and adults. In 2017, Nanostring Technologies, Inc. launched nCounter platform advances as well as new panels expanding the company’s presence in immuno-oncology and 3D biology research. In 2015, Celltrion Healthcare Co., Ltd. launched its Remsima (infliximab), a biosimilar monoclonal antibody (mAb) in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK.

Furthermore, increasing collaborations and acquisitions by major key players in market is also expected to create lucrative environment for growth of market. For instance, in 2016, Biocon Ltd., wholly owned subsidiary of Biocon SA, collaborated with Laboratorios PiSA S.A. de C.V—a Mexico-based company—for the co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market. In 2016, AbbVie Inc. acquired all rights from Boehringer Ingelheim (BI) for Risankizumab (BI 655066). Risankizumab is an anti-IL-23 monoclonal biologic antibody for psoriasis. Company is also evaluating the product for other indications such as Crohn’s disease, asthma, and psoriatic arthritis. Currently, it is in clinical phase 3.

Increasing strategic acquisitions and collaboration by key players is expected to drive market growth in the near future

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. In February 2018, LGC Limited— U.K.-based Company acquired Lucigen Corporation, a U.S.-based developer, and manufacturer of molecular biology enzymes, reagents and kits. Through this strategic acquisition, LGC Limited expanded its portfolio with the Lucigen’s extensive portfolio of NGS kits, enzymes, competent cells, and cloning systems. In February 2018, Servier Laboratories and ImmunoQure AG entered into a strategic collaboration for development of a therapeutic autoantibody neutralizing interferon- a. In March 2018, Wuxi Biologics Co. Ltd. collaborated with Adagene Inc., for the discovery and development of novel antibody therapeutics. In 2017, Omicia, Inc., acquired a bioinformatics startup Spiral Genetics at an undisclosed amount. Through this acquisition of Spiral’s advanced tools, Omicia, Inc., expanded its bioinformatics tools portfolio and strengthened its position in the global market.

Moreover, increasing funding and investments to support the development and research of new biopharmaceutical is also expected to drive the market growth. For instance in 2017, Indian government launched a National Biopharmaceutical Mission. As per the program, the government has invested US $250 Mn that includes a US$ 125 Mn loan from the World Bank to promote development of biological drugs in India. In 2017, The University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) collaborated for the development of new nanomedicine approaches for HIV therapy, and received an award of US$ 3 million from National Institutes of Health (NIH) to generate new technologies and continue research and development.

Cost of biopharmaceutical and biomedicine products are quite high as these need research and development process, and its manufacturing is very complex process, which needs highly skilled scientists. Such expensive biopharmaceutical products are not affordable to organizations in emerging economies such as India, China, and Africa. High cost of biopharmaceutical and biomedicine is a major factor hindering its adoption. For instance, in India a vial of Avastin, a monoclonal antibody, costs between US$ 372.65 to US$ 402.46. High cost medicine is not affordable to everyone, hence, it is a major restraining factor for the market growth. Cost of gene therapy such as Kymriah is very high. Kymriah is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia. The cost of Novartis AG’s cancer therapy Kymriah is about US$ 475,000.

Ask for customization @ https://www.coherentmarketinsights.com/insight/request-customization/18

Key players operating in the global biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.